McKesson looks to strong fiscal 2023 Q4 results amid paltry YTD return

• McKesson (NYSE:NYSE:MCK) is scheduled to announce fiscal 2023 Q4 earnings results on Monday, May 8, after market close.
• The consensus EPS estimate is $7.13 (22% YoY) and the consensus revenue estimate is $67.94B (~3% YoY).
• Over the last 2 years, McKesson (MCK) has beaten EPS estimates four times has beaten revenue estimates four times as well.
• Over the last three months, EPS estimates have seen 13 upward revisions and none downward. Revenue estimates have seen five upward revisions and seven downward ones.
• Seeking Alpha's Quant Rating has viewed McKesson (MCK) as a hold since July 2022.
• Year to date, the stock is down ~3%.
• In fiscal 2023 Q3, the drugs wholesaler beat on the top line but missed on the bottom. But is also raised its non-GAAP EPS guidance range.

More on McKesson

• McKesson Corporation Is A Stable Long-Term Addition

• McKesson Corporation: Looking Forward To Long-Term Low-Teens EPS Growth